Cargando…
BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer
Autores principales: | Lochmann, Timothy L, Bouck, Ynes M, Faber, Anthony C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142900/ https://www.ncbi.nlm.nih.gov/pubmed/30234143 http://dx.doi.org/10.18632/oncoscience.455 |
Ejemplares similares
-
Differentiation therapy: a promising strategy for cancer treatment
por: Yan, Min, et al.
Publicado: (2016) -
Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019) -
Chronic lung disease, lung regeneration and future therapeutic strategies
por: Cao, Xuan-Ye, et al.
Publicado: (2018) -
Bcl‐2/Bcl‐xl inhibitor APG‐1252‐M1 is a promising therapeutic strategy for gastric carcinoma
por: Yi, Hanjie, et al.
Publicado: (2020) -
The Incomplete Puzzle of the BCL2 Proteins
por: Flores-Romero, Hector, et al.
Publicado: (2019)